UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 440

Sortiert nach

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Biochemical journal, 2012-12, Vol.448 (3), p.417-423

2012

Volltextzugriff (PDF)

Conditional Peripheral Membrane Proteins: Facing up to Limited Specificity

Structure (London), 2012-01, Vol.20 (1), p.15-27

2012

Volltextzugriff (PDF)

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

Cancer cell, 2014-11, Vol.26 (5), p.682-694

2014

Volltextzugriff (PDF)

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators

Cell, 2016-03, Vol.164 (6), p.1172-1184

2016

Volltextzugriff (PDF)

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics

Cell, 2017-10, Vol.171 (3), p.683-695.e18

2017

Volltextzugriff (PDF)

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Proceedings of the National Academy of Sciences - PNAS, 2010-04, Vol.107 (17), p.7692-7697

2010

Volltextzugriff (PDF)

Phosphatidylserine binding directly regulates TIM-3 function

Biochemical journal, 2021-09, Vol.478 (17), p.3331-3349

2021

Volltextzugriff (PDF)

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

Nature (London), 2022-02, Vol.602 (7897), p.518-522

2022

Volltextzugriff (PDF)

Insulin and epidermal growth factor receptor family members share parallel activation mechanisms

Protein science, 2020-06, Vol.29 (6), p.1331-1344

2020

Volltextzugriff (PDF)

Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor

Cell reports (Cambridge), 2014-11, Vol.9 (4), p.1306-1317

2014

Volltextzugriff (PDF)

Phosphoinositide Recognition Domains

Traffic (Copenhagen, Denmark), 2003-04, Vol.4 (4), p.201-213

Lemmon, Mark A.

2003

Volltextzugriff (PDF)

Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor

Cell, 2010-08, Vol.142 (4), p.568-579

2010

Volltextzugriff (PDF)

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Molecular cell, 2009-06, Vol.34 (6), p.641-651

2009

Volltextzugriff (PDF)

Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients

The EMBO journal, 2010-09, Vol.29 (18), p.3054-3067

2010

Volltextzugriff (PDF)

Membrane recognition by phospholipid-binding domains

Nature reviews. Molecular cell biology, 2008-02, Vol.9 (2), p.99-111

Lemmon, Mark A

2008

Volltextzugriff (PDF)

TIPE3 Is the Transfer Protein of Lipid Second Messengers that Promote Cancer

Cancer cell, 2014-10, Vol.26 (4), p.465-478

2014

Volltextzugriff (PDF)

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Cancer discovery, 2016-01, Vol.6 (1), p.96-107

2016

Volltextzugriff (PDF)

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (38), p.E3595-E3604

2013

Volltextzugriff (PDF)

Cell Signaling by Receptor Tyrosine Kinases

Cell, 2010-06, Vol.141 (7), p.1117-1134

2010

Volltextzugriff (PDF)

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Clinical cancer research, 2019-11, Vol.25 (21), p.6382-6391

2019

Volltextzugriff (PDF)

Putting together structures of epidermal growth factor receptors

Current opinion in structural biology, 2014-12, Vol.29, p.95-101

2014

Volltextzugriff (PDF)

Allosteric activation of the co-receptor BAK1 by the EFR receptor kinase initiates immune signaling

eLife, 2024-07, Vol.12

2024

Volltextzugriff (PDF)

Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase

Biochemical journal, 2017-02, Vol.474 (3), p.385-398

2017

Volltextzugriff (PDF)

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Nature communications, 2022-11, Vol.13 (1), p.6791-6791, Article 6791

2022

Volltextzugriff (PDF)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Nature communications, 2023-05, Vol.14 (1), p.2601-2601, Article 2601

2023

Volltextzugriff (PDF)

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(413)
Mit Volltextzugriff
(416)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Conditional Peripheral Membrane Proteins: Facing up to Limited Specificity

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Phosphatidylserine binding directly regulates TIM-3 function

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

Insulin and epidermal growth factor receptor family members share parallel activation mechanisms

Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor

Phosphoinositide Recognition Domains

Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients

Membrane recognition by phospholipid-binding domains

TIPE3 Is the Transfer Protein of Lipid Second Messengers that Promote Cancer

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

Cell Signaling by Receptor Tyrosine Kinases

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Putting together structures of epidermal growth factor receptors

Allosteric activation of the co-receptor BAK1 by the EFR receptor kinase initiates immune signaling

Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Suchergebnisse filtern